Israeli company Gamida Cell announced today that it has closed an internal financing round of $10 million from all major shareholders. According to the company, the financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx. The product is in development as an alternative therapeutic treatment for patients with blood cancers, such as leukemia and lymphoma who can be cured by bone marrow transplantation but do not have a matched bone marrow donor.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Red Algae Can Treat Wounds And Infections
January 26, 2023

Freight Planner Lists on Nasdaq And Raises $80M
January 26, 2023

$6M Investment For “Lettuce Milk” Startup
January 25, 2023

Israel Has World’s Best Value Internet
January 25, 2023
Facebook comments